Intravenous Tranexamic Acid Reduces Perioperative Blood Loss in Reduction Mammoplasty With Immediate Implant-Based Reconstruction: A Randomized, Triple-Blinded, Placebo-Controlled Trial.
Aesthet Surg JSep 16, 2026
Jerzy Kolasiński, Tomasz Reysner, Małgorzata Kolenda et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized, triple-blinded, placebo-controlled trial evaluated the effect of intravenous tranexamic acid (TXA) on perioperative blood loss in 60 women undergoing bilateral reduction mammoplasty with immediate implant-based reconstruction. The study found that total blood loss was significantly lower in the TXA group compared to placebo, with a mean difference of -77.0 mL (P = .001).
Key findings
- Total blood loss was 221.1 ± 72.4 mL with TXA vs 298.1 ± 90.6 mL with placebo.
- Postoperative D-dimer levels were lower in the TXA group (0.31 ± 0.15 vs 0.49 ± 0.22 µg/mL; P = .002).
- Intraoperative blood loss and 24-hour drain output were also reduced with TXA.
Why it matters
Reducing perioperative blood loss can enhance surgical outcomes and recovery in patients undergoing reduction mammoplasty. The use of TXA may improve patient safety and reduce complications associated with excessive bleeding.